Literature DB >> 19595354

Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects.

Giovanni Guaraldi1, Chiara Stentarelli, Stefano Zona, Gabriella Orlando, Federica Carli, Guido Ligabue, Antonella Lattanzi, Giacomo Zaccherini, Rosario Rossi, Maria Grazia Modena, Nikolaos Alexopoulos, Frank Palella, Paolo Raggi.   

Abstract

BACKGROUND AND
OBJECTIVE: Although anti-retroviral therapy (ART) prolonged survival in HIV-infected persons, an increase in cardiovascular disease has also been observed. A frequent complication of ART is the development of lipodystrophy (LD) with its multiple phenotypes that may be associated with cardiovascular disease. We assessed the contribution of chronic HIV infection, ART use and LD to the presence of sub-clinical atherosclerosis as evaluated by coronary artery calcium (CAC) imaging.
METHODS: Observational cross-sectional study of 372 HIV-infected patients receiving ART who attended a cardiometabolic clinic (48.2+/-8-year old; 74% men). All patients underwent CAC surveillance with computed tomography and the Agatston score was used to quantitate CAC. Presence of CAC was defined as a score >10. Multivariable logistic regression was used to evaluate associations between HIV clinical factors, ART and LD with the presence of CAC.
FINDINGS: CAC was found in 134 patients (36%) with a median CAC score of 50 (range 10; 1243). Lipoatrophy alone (OR 3.82, 95% CI: 1.11; 13.1), fat accumulation alone (OR 7.65, 95% CI: 1.71; 37.17) and mixed lipodystrophy phenotypes (OR 4.36, 95% CI: 1.26; 15.01) were strongly associated with presence of CAC after adjusting for age, sex, hypertension and cumulative exposure to ART.
CONCLUSION: CAC is common among long-term ART users. The association between CAC and LD underscores the potential atherosclerosis risk inherent with ART and the need to undertake routine cardiovascular surveillance in patients treated with these drugs. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19595354     DOI: 10.1016/j.atherosclerosis.2009.06.011

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  29 in total

1.  Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Authors:  Takara L Stanley; Julian Falutz; Jean-Claude Mamputu; Graziella Soulban; Diane Potvin; Steven K Grinspoon
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

2.  Lenalidomide enhancement of human T cell functions in human immunodeficiency virus (HIV)-infected and HIV-negative CD4 T lymphocytopenic patients.

Authors:  H Lim; L Kane; J B Schwartz; C S Hesdorffer; S G Deeks; N Greig; L Ferrucci; E J Goetzl
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

3.  Coronary risk assessment in patients with HIV infection: why bother?

Authors:  Stefan Möhlenkamp; Nico Reinsch; Raimund Erbel; Till Neumann
Journal:  Int J Cardiovasc Imaging       Date:  2011-08-26       Impact factor: 2.357

4.  Chromium Therapy for Insulin Resistance Associated with HIV-Disease.

Authors:  Seth A Stein; Margaret Mc Nurlan; Brett T Phillips; Catherine Messina; Dennis Mynarcik; Marie Gelato
Journal:  J AIDS Clin Res       Date:  2013-09-07

Review 5.  Pathogenesis and treatment of HIV lipohypertrophy.

Authors:  Vivien L Leung; Marshall J Glesby
Journal:  Curr Opin Infect Dis       Date:  2011-02       Impact factor: 4.915

6.  Progression of coronary artery calcium in men affected by human immunodeficiency virus infection.

Authors:  Giovanni Guaraldi; Stefano Zona; Gabriella Orlando; Federica Carli; Guido Ligabue; Federica Fiocchi; Rosario Rossi; Maria Grazia Modena; Paolo Raggi
Journal:  Int J Cardiovasc Imaging       Date:  2011-06-05       Impact factor: 2.357

7.  Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Authors:  Giovanni Guaraldi; Stefano Zona; Gabriella Orlando; Federica Carli; Chiara Stentarelli; Kety Luzi; Elisa Garlassi; Marianna Menozzi; Pietro Bagni; Fulvio Adorni
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

8.  Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

Authors:  Priya Bhagwat; Ighovwerha Ofotokun; Grace A McComsey; Todd T Brown; Carlee Moser; Catherine A Sugar; Judith S Currier
Journal:  Antivir Ther       Date:  2017-03-01

Review 9.  Nutritional and metabolic correlates of cardiovascular and bone disease in HIV-infected patients.

Authors:  Kathleen Fitch; Steven Grinspoon
Journal:  Am J Clin Nutr       Date:  2011-11-16       Impact factor: 7.045

Review 10.  Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.

Authors:  Ovidiu Galescu; Amrit Bhangoo; Svetlana Ten
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.